IQV
IQV clinical trials: IQVIA HOLDINGS INC.
Every trial on ClinicalTrials.gov where IQVIA HOLDINGS INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 149
- Trials linked
- 2
- As lead sponsor
- 147
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IQV on the catalyst calendar · IQV registry changes
- Primary completion Feb 23, 2023ActualNo phase registeredNCT04368065COVID-19 Active Research Experience (CARE)IQVIA Pty Ltd · COVID-19CompletedIQVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 29, 2020ActualPhase 1NCT04025307Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid TumoursIQVIA Pty Ltd · Cancer - Solid TumoursTerminatedIQVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 2NCT03767075A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)Vall d'Hebron Institute of Oncology · Advanced Solid TumorRecruitingJNJCollaboratorIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT07377682Real-world Clinical Response to Trazodone in Italy, Poland, and RomaniaAziende Chimiche Riunite Angelini Francesco S.p.A · Depression - Major Depressive DisorderRecruitingIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2026ActualNo phase registeredNCT06716801Real-world Clinical Response to Cenobamate Early add-on in France, Germany and SpainAziende Chimiche Riunite Angelini Francesco S.p.A · Focal Epilepsy With and Without Secondary GeneralizationCompletedIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2025ActualNo phase registeredNCT05859854Cenobamate in Adults With Focal-Onset SeizuresAziende Chimiche Riunite Angelini Francesco S.p.A · EpilepsyCompletedIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 17, 2031Sponsor estimatePhase 3NCT07898774A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant...Swedish Orphan Biovitrum · C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)RecruitingIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2026ActualNo phase registeredNCT06498128Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®Idorsia Pharmaceuticals Ltd. · InsomniaTerminatedIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 18, 2025ActualPhase 3NCT05101187Olorofim Aspergillus Infection StudyF2G Ltd · Invasive AspergillosisCompletedIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 14, 2028Sponsor estimateNo phase registeredNCT07856810Randomized Evaluation of Lumbar Injection Effectiveness and FunctionSpinaFX Medical Inc. · Lumbar RadiculopathyNot yet recruitingIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 15, 2025ActualNo phase registeredNCT04280029SELUTION SLR™ 014 In-stent RestenosisM.A. Med Alliance S.A. · Coronary RestenosisActive, not recruitingIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2027Sponsor estimateNo phase registeredNCT06559891THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of HypertensionSoniVie Inc. · HypertensionRecruitingIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2030Sponsor estimateNo phase registeredNCT07049653Anifrolumab Pregnancy StudyAstraZeneca · Systemic Lupus ErythematosusRecruitingAZNLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2031Sponsor estimateNo phase registeredNCT07000110Anifrolumab Malignancy and Serious Infections StudyAstraZeneca · Systemic Lupus ErythematosusRecruitingAZNLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 18, 2023ActualPhase 3NCT02678572Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaDelcath Systems Inc. · Ocular MelanomaCompletedDCTHLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2031Sponsor estimatePhase 4NCT07746895Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country StudySwedish Orphan Biovitrum · C3 Glomerulopathy (C3G)RecruitingIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 15, 2029Sponsor estimateNo phase registeredNCT05776472A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Swedish Orphan Biovitrum · Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 6, 2021Sponsor estimateEarly Phase 1NCT04123574A Pilot Study of BXCL701 in Patients With Pancreatic CancerBioXcel Therapeutics Inc · Cancer of PancreasWithdrawnBTAIQLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 22, 2025ActualPhase 3NCT04877691Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusAstraZeneca · Systemic Lupus ErythematosusActive, not recruitingAZNLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2026Sponsor estimateNo phase registeredNCT06712563Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care SettingAstraZeneca · Pulmonary Disease, Chronic ObstructiveActive, not recruitingAZNLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2025ActualPhase 1NCT03881488Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally...Compass Therapeutics · Locally Advanced Solid TumorTerminatedCMPXLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 17, 2021ActualPhase 1/Phase 2NCT02734004A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.AstraZeneca · OvarianActive, not recruitingAZNLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2029Sponsor estimateNo phase registeredNCT03193476Registry for Patients With X-Linked HypophosphatemiaKyowa Kirin Pharmaceutical Development Ltd · X-Linked HypophosphatemiaRecruitingIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 3NCT05908084To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisHumacyte, Inc. · End Stage Renal Disease (ESRD)Active, not recruitingHUMALeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2026Sponsor estimatePhase 2NCT06504446Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic CoughNocion Therapeutics · Refractory or Unexplained Chronic CoughActive, not recruitingIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 124 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner